Zhejiang Medicine Co., Ltd. (SHA: 600216)

Market Cap	17.20B
Revenue (ttm)	9.03B
Net Income (ttm)	977.95M
Shares Out	961.64M
EPS (ttm)	1.02
PE Ratio	17.48
Forward PE	12.39
Dividend	0.15 (0.84%)
Ex-Dividend Date	Jul 10, 2024

Volume	36,349,872
Open	17.95
Previous Close	18.18
Day's Range	17.64 - 18.09
52-Week Range	7.97 - 19.40
Beta	0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceutical products in China. The company products include synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also offers fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company provides injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin products....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 6,227
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2023, Zhejiang Medicine's revenue was 7.79 billion, a decrease of -3.96% compared to the previous year's 8.12 billion. Earnings were 429.64 million, a decrease of -20.37%.